A new trading day began on Monday, with CRISPR Therapeutics AG (NASDAQ: CRSP) stock price up 6.28% from the previous day of trading, before settling in for the closing price of $51.62. CRSP’s price has ranged from $43.42 to $91.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 33402.13% over the past five years. Meanwhile, its annual earnings per share averaged -170.07%. With a float of $81.64 million, this company’s outstanding shares have now reached $85.35 million.
Let’s look at the performance matrix of the company that is accounted for 407 employees. In terms of profitability, gross margin is 30.6%, operating margin of -164.86%, and the pretax margin is -117.29%.
CRISPR Therapeutics AG (CRSP) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CRISPR Therapeutics AG is 4.35%, while institutional ownership is 65.70%. The most recent insider transaction that took place on Oct 14 ’24, was worth 50,399. In this transaction General Counsel and Secretary of this company sold 1,089 shares at a rate of $46.28, taking the stock ownership to the 62,597 shares. Before that another transaction happened on Oct 14 ’24, when Company’s Chief Executive Officer sold 4,293 for $46.28, making the entire transaction worth $198,680. This insider now owns 226,540 shares in total.
CRISPR Therapeutics AG (CRSP) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of 1.1 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -170.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 10.83% growth over the previous five years of trading.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Here are CRISPR Therapeutics AG’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 21.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.82, a number that is poised to hit -1.26 in the next quarter and is forecasted to reach -5.04 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (NASDAQ: CRSP) saw its 5-day average volume 2.2 million, a positive change from its year-to-date volume of 1.47 million. As of the previous 9 days, the stock’s Stochastic %D was 74.56%. Additionally, its Average True Range was 2.48.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 56.47%, which indicates a significant decrease from 69.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.20% in the past 14 days, which was higher than the 47.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.60, while its 200-day Moving Average is $57.84. Nevertheless, the first resistance level for the watch stands at $58.29 in the near term. At $61.71, the stock is likely to face the second major resistance level. The third major resistance level sits at $64.36. If the price goes on to break the first support level at $52.22, it is likely to go to the next support level at $49.57. Assuming the price breaks the second support level, the third support level stands at $46.15.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
With a market capitalization of 4.66 billion, the company has a total of 85,353K Shares Outstanding. Currently, annual sales are 371,210 K while annual income is -153,610 K. The company’s previous quarter sales were 520 K while its latest quarter income was -126,410 K.
